These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 37097894)

  • 21. Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study.
    McInnes IB; Mease PJ; Ritchlin CT; Rahman P; Gottlieb AB; Kirkham B; Kajekar R; Delicha EM; Pricop L; Mpofu S
    Rheumatology (Oxford); 2017 Nov; 56(11):1993-2003. PubMed ID: 28968735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of secukinumab and adalimumab in patients with psoriatic arthritis and concomitant moderate-to-severe plaque psoriasis: results from EXCEED, a randomized, double-blind head-to-head monotherapy study.
    Gottlieb AB; Merola JF; Reich K; Behrens F; Nash P; Griffiths CEM; Bao W; Pellet P; Pricop L; McInnes IB
    Br J Dermatol; 2021 Dec; 185(6):1124-1134. PubMed ID: 33913511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial.
    Baraliakos X; Sewerin P; de Miguel E; Pournara E; Kleinmond C; Shekhawat A; Jentzsch C; Wiedon A; Behrens F;
    Arthritis Res Ther; 2022 May; 24(1):111. PubMed ID: 35578245
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted systemic therapies for psoriatic arthritis: a systematic review and comparative synthesis of short-term articular, dermatological, enthesitis and dactylitis outcomes.
    McInnes IB; Sawyer LM; Markus K; LeReun C; Sabry-Grant C; Helliwell PS
    RMD Open; 2022 Mar; 8(1):. PubMed ID: 35321874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of TNF-α inhibition
    Elliott A; Wright G; Pendleton A; Rooney M
    Ther Adv Musculoskelet Dis; 2023; 15():1759720X231179524. PubMed ID: 38024204
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Course of Magnetic Resonance Imaging-Detected Inflammation and Structural Lesions in the Sacroiliac Joints of Patients in the Randomized, Double-Blind, Placebo-Controlled Danish Multicenter Study of Adalimumab in Spondyloarthritis, as Assessed by the Berlin and Spondyloarthritis Research Consortium of Canada Methods.
    Pedersen SJ; Poddubnyy D; Sørensen IJ; Loft AG; Hindrup JS; Thamsborg G; Asmussen K; Hendricks O; Nørregaard J; Piil AD; Møller JM; Jurik AG; Balding L; Lambert RG; Sieper J; Østergaard M
    Arthritis Rheumatol; 2016 Feb; 68(2):418-29. PubMed ID: 26414004
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study.
    Korotaeva TV; Loginova EY; Getiya TS; Nasonov EL
    Ter Arkh; 2018 May; 90(5):22-29. PubMed ID: 30701886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
    Mease PJ; Blachley T; Dube B; McLean RR; Kim N; Hur P; Ogdie A
    J Rheumatol; 2022 Jul; 49(7):700-706. PubMed ID: 35428716
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial.
    Walsh JA; Gottlieb AB; Hoepken B; Nurminen T; Mease PJ
    Clin Rheumatol; 2018 Dec; 37(12):3285-3296. PubMed ID: 30191421
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Disease-Modifying Antirheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort.
    Mathew AJ; Sutton M; Pereira D; Gladman DD; Chandran V
    J Rheumatol; 2022 Sep; 49(9):1020-1025. PubMed ID: 35649547
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial.
    Gladman DD; Mease PJ; Bird P; Soriano ER; Chakravarty SD; Shawi M; Xu S; Quinn ST; Gong C; Leibowitz E; Poddubnyy D; Tam LS; Helliwell PS; Kavanaugh A; Deodhar A; Østergaard M; Baraliakos X
    Trials; 2022 Sep; 23(1):743. PubMed ID: 36064592
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of TNF-α inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients.
    Narcisi A; Valenti M; De Simone C; Esposito M; Richetta A; Teoli M; Argento G; Costanzo A
    J Dermatolog Treat; 2022 May; 33(3):1703-1706. PubMed ID: 33691568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.
    Strand V; Betts KA; Mittal M; Song J; Skup M; Joshi A
    Rheumatol Ther; 2017 Dec; 4(2):349-362. PubMed ID: 28762213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adalimumab markedly improves enthesitis in patients with psoriatic arthritis: Evaluation with a magnetic resonance imaging scoring system.
    Yanaba K; Sadaoka A; Yonenaga T; Saeki H; Umezawa Y; Tojo S; Ito T; Kikuchi S; Fukuda K; Nakagawa H
    J Dermatol; 2015 Dec; 42(12):1153-9. PubMed ID: 26109492
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound.
    Kristensen S; Christensen JH; Schmidt EB; Olesen JL; Johansen MB; Arvesen KB; Schlemmer A
    Muscles Ligaments Tendons J; 2016; 6(2):241-247. PubMed ID: 27900299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis.
    Healy PJ; Helliwell PS
    Arthritis Rheum; 2008 May; 59(5):686-91. PubMed ID: 18438903
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measuring treatment effect on psoriatic arthritis-related domains: insights from the SPIRIT-H2H study at weeks 24 and 52.
    Behrens F; Leage SL; Sapin C; Baou CE; De La Torre I; Meszaros G; Schett G; Combe B; van den Bosch F; Gossec L
    Clin Rheumatol; 2021 Dec; 40(12):4943-4954. PubMed ID: 34515902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis and improves health-related quality of life in patients achieving remission: 2-year results from the phase III FUTURE 2 study.
    Coates LC; Gladman DD; Nash P; FitzGerald O; Kavanaugh A; Kvien TK; Gossec L; Strand V; Rasouliyan L; Pricop L; Ding K; Jugl SM; Gaillez C;
    Arthritis Res Ther; 2018 Dec; 20(1):272. PubMed ID: 30526678
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52.
    Smolen JS; Mease P; Tahir H; Schulze-Koops H; de la Torre I; Li L; Hojnik M; Sapin C; Okada M; Caporali R; Gratacós J; Goupille P; Liu Leage S; Pillai S; Nash P
    Ann Rheum Dis; 2020 Oct; 79(10):1310-1319. PubMed ID: 32660977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.
    Rudwaleit M; Van den Bosch F; Kron M; Kary S; Kupper H
    Arthritis Res Ther; 2010; 12(3):R117. PubMed ID: 20553600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.